To Evaluate if the Medication Gabapentin Lessens Vulvar Pain
TerminatedNot applicableNCT00390013
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The purpose of this research study is to evaluate if the medication gabapentin lessens the vulvar pain some women experience.
Study details
- Official title
- Vulvar Pain: Treatment Trial Using Gabapentin-placebo in a Cross-over Design, Pilot Study.
- Conditions
- Vulvar Pain Symptoms
- Vulvodynia (Chronic Vulvar Pain)
- Interventions
- Sponsor
- Colleen Stockdale
- Organization
- University of Iowa
- Start date
- 2007-01
- Primary completion
- 2008-03
- Sex
- Female
- Age range
- from 18 Years to 80 Years
- Healthy volunteers
- true
- Results posted
- Yes, on ClinicalTrials.gov
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * All women, ages 18 years and older with the diagnosis of vulvodynia or VVS (by Friedrich's criteria), who present to the University of Iowa Vulvar Vaginal Disease Clinic. Exclusion Criteria: * Vulvar Vaginal Disease clinic patients who are pregnant, less than 3 months postpartum, breast-feeding, non-English speaking, or have contraindication to use of gabapentin due to allergy or renal disease (serum creatinine level greater than 1.4).
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00390013